Molecule Details
| InChIKey | WPEWQEMJFLWMLV-UHFFFAOYSA-N |
|---|---|
| Canonical SMILES | N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.98 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB14765 |
|---|---|
| Drug Name | Rivoceranib |
| CAS Number | 811803-05-1 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer). |
Categories: Antineoplastic Agents Enzyme Inhibitors Protein Kinase Inhibitors
Cross-references: CHEMBL3186534 ChemSpider: 9490441 Wikipedia: Apatinib ZINC: ZINC000070466461
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P35968 | KDR | Vascular endothelial growth factor receptor 2 | inhibitor | targets |